POOLED SAFETY AND ADVERSE EVENTS IN NINE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 AND 3 CLINICAL TRIALS OF ALIROCUMAB

Overview of attention for article published in JACC, March 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 24 patents

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 24 patents that reference this research output.

Stabilized formulations containing anti-PCSK9 antibodies

Grant US-12612466-B2

United States of America

28 Apr 2026

Dosing regimens for use with PCSK9 inhibitors

Grant US-12606638-B2

United States of America

21 Apr 2026

Anti-PCSK9 antibodies

Grant US-12269897-B2

United States of America

08 Apr 2025

Human antibodies to PCSK9 for use in methods of treating particular groups of subjects

Grant US-12083176-B2

United States of America

10 Sep 2024

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 20 additional patents.